What To Know
- David Adair, MD, MBA, Managing Partner of Solas BioVentures stated, “InterShunt’s innovative and differentiated approach to create an interatrial shunt has the potential to provide significant clinical benefit in a space that has limited options.
- , an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced today the completion of an equity financing.
January 11, 2021
InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced today the completion of an equity financing.
InterShunt Technologies said the funding will be used to support the research and development of the Percutaneous Atrial Shunt Catheter System (PAS-C™ System).
The round was led by Solas BioVentures with participation from Arsenal Capital Management and a select group of industry executives advises Intershunt Technologies.
David Adair, MD, MBA, Managing Partner of Solas BioVentures stated, “InterShunt’s innovative and differentiated approach to create an interatrial shunt has the potential to provide significant clinical benefit in a space that has limited options. The ability to create a shunt without energy or hardware is attractive. Leaving nothing behind allows the body the best chance at superb outcomes. We seek out opportunities like InterShunt that use exquisite solutions based on physiology to help relieve human suffering. We are thrilled to lead this round in support of a company with such outstanding tech and industry legends.”
Harlee Sorkin, CEO of InterShunt Technologies commented, “We’re excited to have the Solas team back our vision to create a best-in-class interatrial shunt. Their investment coupled with Arsenal’s long-standing support of our program enables us to advance our design and obtain key pre-clinical and human data.”
